| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Osmotica Pharmaceuticals plc (NASDAQ: OSMT)
OSMT Technical Analysis
5
| As on 22nd Mar 2022 OSMT STOCK Price closed @ 1.87 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 4.14 & Strong Sell for SHORT-TERM with Stoploss of 5.87 we also expect STOCK to react on Following IMPORTANT LEVELS. |
OSMTSTOCK Price
| Open | 1.93 | Change | Price | % |
| High | 1.93 | 1 Day | 0.01 | 0.54 |
| Low | 1.84 | 1 Week | 0.11 | 6.25 |
| Close | 1.87 | 1 Month | 0.74 | 65.49 |
| Volume | 214580 | 1 Year | -3.93 | -67.76 |
| 52 Week High 6.29 | 52 Week Low 0.98 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| OSMT Daily Charts |
OSMT Intraday Charts |
Whats New @ Bazaartrend |
OSMT Free Analysis |
|
|
OSMT Important Levels Intraday
| RESISTANCE | 2.04 |
| RESISTANCE | 1.99 |
| RESISTANCE | 1.95 |
| RESISTANCE | 1.92 |
| SUPPORT | 1.82 |
| SUPPORT | 1.79 |
| SUPPORT | 1.75 |
| SUPPORT | 1.70 |
OSMT Forecast May 2024
| 4th UP Forecast | 4.45 |
| 3rd UP Forecast | 3.62 |
| 2nd UP Forecast | 3.11 |
| 1st UP Forecast | 2.6 |
| 1st DOWN Forecast | 1.14 |
| 2nd DOWN Forecast | 0.63 |
| 3rd DOWN Forecast | 0.12 |
| 4th DOWN Forecast | -0.71 |
OSMT Weekly Forecast
| 4th UP Forecast | 3.35 |
| 3rd UP Forecast | 2.88 |
| 2nd UP Forecast | 2.58 |
| 1st UP Forecast | 2.29 |
| 1st DOWN Forecast | 1.45 |
| 2nd DOWN Forecast | 1.16 |
| 3rd DOWN Forecast | 0.86 |
| 4th DOWN Forecast | 0.39 |
OSMT Forecast2024
| 4th UP Forecast | 12.49 |
| 3rd UP Forecast | 9.08 |
| 2nd UP Forecast | 6.98 |
| 1st UP Forecast | 4.87 |
| 1st DOWN Forecast | -1.13 |
| 2nd DOWN Forecast | -3.24 |
| 3rd DOWN Forecast | -5.34 |
| 4th DOWN Forecast | -8.75 |
Osmotica Pharmaceuticals plc ( NASDAQ USA Symbol : OSMT )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
OSMT Business Profile
Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products in the United States, Argentina, and Hungary. The company's promoted products include M-72, a methylphenidate hydrochloride extended-release tablet to treat attention deficit hyperactivity disorder (ADHD); Osmolex ER, an amantadine extended-release tablet for the treatment of Parkinson's disease and drug-induced extrapyramidal reactions in adults; Arbaclofen extended-release tablets which is in phase III clinical trial for the treatment of multiple sclerosis spasticity; Upneeq, an oxymetazoline hydrochloride ophthalmic solution for the treatment of Blepharoptosis; and OS870 which is in Phase I clinical trial for the treatment of neurodegenerative disorders. It also provides women's health products, including Divigel for menopause; and OB Complete, a dietary supplement for prenatal, pregnancy, and postnatal periods. In addition, the company's non-promoted products comprise methylphenidate ER tablets for ADHD; venlafaxine ER tablets to treat major depressive disorders and social anxiety disorders; hydromorphone ER for treating pain; nifedipine ER for hypertension; sodium benzoate/sodium phenylacetate for the treatment of hyperammonemia; oxybutynin ER for overactive bladder; prescription prenatal vitamins for treating nutritional requirements during pregnancy; Lorzone, an immediate-release form of chlorzoxazone indicated for the treatment of acute musculoskeletal pain in conjunction with rest and physical therapy; ConZip, a tramadol hydrochloride for the management of pain; and nitrofurantoin for the treatment of urinary tract infections, as well as Osmodex and other abbreviated new drug applications. Osmotica Pharmaceuticals plc is headquartered in Bridgewater, New Jersey. Address: 400 Crossing Boulevard, Bridgewater, NJ, United States, 08807
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service